






Nonsteroidal Anti-inflammatory Drugs Alter the Microbiota and Exacerbate *Clostridium difficile* Colitis while Dysregulating the Inflammatory Response

 Damian Maseda,^{a*}  Joseph P. Zackular,^{a*} Bruno Trindade,^b Leslie Kirk,^b Jennifer Lising Roxas,^d Lisa M. Rogers,^b Mary K. Washington,^a Liping Du,^e Tatsuki Koyama,^e V. K. Viswanathan,^d Gayatri Vedantam,^d  Patrick D. Schloss,^c Leslie J. Crofford,^b Eric P. Skaar,^a David M. Aronoff^{a,b}

^aDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA

^bDepartment of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA

^cDepartment of Microbiology and Immunology, University of Michigan, Ann Arbor, Michigan, USA

^dSchool of Animal and Comparative Biomedical Sciences, University of Arizona, Tucson, Arizona, USA

^eCenter for Quantitative Sciences, Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, Tennessee, USA

ABSTRACT *Clostridium difficile* infection (CDI) is a major public health threat worldwide. The use of nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with enhanced susceptibility to and severity of CDI; however, the mechanisms driving this phenomenon have not been elucidated. NSAIDs alter prostaglandin (PG) metabolism by inhibiting cyclooxygenase (COX) enzymes. Here, we found that treatment with the NSAID indomethacin prior to infection altered the microbiota and dramatically increased mortality and the intestinal pathology associated with CDI in mice. We demonstrated that in *C. difficile*-infected animals, indomethacin treatment led to PG deregulation, an altered proinflammatory transcriptional and protein profile, and perturbed epithelial cell junctions. These effects were paralleled by increased recruitment of intestinal neutrophils and CD4⁺ cells and also by a perturbation of the gut microbiota. Together, these data implicate NSAIDs in the disruption of protective COX-mediated PG production during CDI, resulting in altered epithelial integrity and associated immune responses.

IMPORTANCE *Clostridium difficile* infection (CDI) is a spore-forming anaerobic bacterium and leading cause of antibiotic-associated colitis. Epidemiological data suggest that use of nonsteroidal anti-inflammatory drugs (NSAIDs) increases the risk for CDI in humans, a potentially important observation given the widespread use of NSAIDs. Prior studies in rodent models of CDI found that NSAID exposure following infection increases the severity of CDI, but mechanisms to explain this are lacking. Here we present new data from a mouse model of antibiotic-associated CDI suggesting that brief NSAID exposure prior to CDI increases the severity of the infectious colitis. These data shed new light on potential mechanisms linking NSAID use to worsened CDI, including drug-induced disturbances to the gut microbiome and colonic epithelial integrity. Studies were limited to a single NSAID (indomethacin), so future studies are needed to assess the generalizability of our findings and to establish a direct link to the human condition.

KEYWORDS *Clostridium difficile*, colitis, gut inflammation, immune dysfunction, immune response, inflammation, intestinal immunity, prostaglandin

Clostridium difficile is the most commonly reported nosocomial pathogen in the United States and an urgent public health threat worldwide (1). *C. difficile* infection (CDI) manifests as a spectrum of gastrointestinal disorders ranging from mild diarrhea

Citation Maseda D, Zackular JP, Trindade B, Kirk L, Roxas JL, Rogers LM, Washington MK, Du L, Koyama T, Viswanathan VK, Vedantam G, Schloss PD, Crofford LJ, Skaar EP, Aronoff DM. 2019. Nonsteroidal anti-inflammatory drugs alter the microbiota and exacerbate *Clostridium difficile* colitis while dysregulating the inflammatory response. *mBio* 10:e02282-18. <https://doi.org/10.1128/mBio.02282-18>.

Editor Jimmy D. Ballard, University of Oklahoma Health Sciences Center

Copyright © 2019 Maseda et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to David M. Aronoff, d.aronoff@vanderbilt.edu.

* Present address: Damian Maseda, Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; Joseph P. Zackular, Department of Pathology and Laboratory Medicine, University of Pennsylvania and Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. D.M. and J.P.Z. contributed equally to this article.

Received 18 October 2018

Accepted 28 November 2018

Published 8 January 2019

to toxic megacolon and/or death, particularly in older adults (2). The primary risk factor for CDI is antibiotic treatment, which perturbs the resident gut microbiota and abolishes colonization resistance (3). However, factors other than antibiotic exposure increase the risk for CDI and the incidence of cases not associated with the use of antimicrobials has been on the rise (4). Defining mechanisms whereby nonantibiotic factors impact CDI pathogenesis promises to reveal actionable targets for preventing or treating this infection.

Recently, several previously unappreciated immune system, host, microbiota, and dietary factors have emerged as modulators of CDI severity and risk. The food additive trehalose, for example, was recently shown to increase *C. difficile* virulence in mice, and the widespread adoption of trehalose in food products was implicated in the emergence of hypervirulent strains of *C. difficile* (5). Similarly, excess dietary zinc had a profound impact on severity of *C. difficile* disease in mice, and high levels of zinc altered the gut microbiota and increased susceptibility to CDI (6). Importantly, there is a growing body of evidence of the essential role of the innate immune response and inflammation in both protection against and pathology of CDI (7–9). Mounting a proper and robust inflammatory response is critical for successful clearance of *C. difficile*, and the immune response can be a key predictor of prognosis (3, 10). In this context, specific immune mediators can facilitate both protective and pathogenic responses through the activity of molecules such as interleukin-23 (IL-23) and IL-22, and an excessive and dysregulated immune response is believed to be one of the main factors behind postinfection complications.

Epidemiological data have established an association between the use of nonsteroidal anti-inflammatory drugs (NSAIDs) and CDI (11). Muñoz-Miralles and colleagues demonstrated that the NSAID indomethacin (Indo) significantly increased the severity of CDI in antibiotic-treated mice when the NSAID was applied following inoculation and throughout the infection (12), and indomethacin exposure is associated with alterations in the structure of the intestinal microbiota (13, 14). NSAIDs are among the most highly prescribed and most widely consumed drugs in the United States (15), particularly among older adults (16), and have been implicated in causing spontaneous colitis in humans (17, 18). They act by inhibiting cyclooxygenase (COX) enzymatic activity, which prevents the generation of prostaglandins (PGs) and alters the outcome of subsequent inflammatory events. Prostaglandins, especially PGE₂, are important lipid mediators that are highly abundant at sites of inflammation and infection and that support gastrointestinal homeostasis and epithelial cell (EC) health (19). NSAID use has been associated with shifts in the gut microbiota, in both rodents and humans (20–23), but these shifts have not been explored in the context of CDI.

In this report, we deployed a mouse model of antibiotic-associated CDI to examine the impact of exposure to indomethacin prior to infection with *C. difficile* on disease severity, immune response, intestinal epithelial integrity, and the gut microbiota. These investigations revealed that even a brief exposure to an NSAID prior to *C. difficile* inoculation dramatically increased CDI severity, reduced survival, and increased pathological evidence of disease. Inhibition of PG biosynthesis by indomethacin altered the cytokine response and immune cell recruitment following CDI, enhancing intestinal tissue histopathology and allowing partial systemic bacterial dissemination by dismantling intestinal epithelial tight junctions (TJs). Additionally, indomethacin treatment alone significantly perturbed the structure of the gut microbiota. These findings support epidemiological data linking NSAID use and CDI and caution against the overuse of NSAIDs in patients at high risk for *C. difficile*, such as older adults.

RESULTS

Indomethacin worsens *C. difficile* Infection in Mice and Increases Mortality. To determine the extent to which preexposure to NSAIDs influences the natural course of CDI, mice were treated with indomethacin for 2 days prior to inoculation with *C. difficile* (Fig. 1A). We infected C57BL/6 female mice with 1×10^4 spores of *C. difficile* NAP1/BI/027 strain M7404 following 5 days of pretreatment with a broad-spectrum antibiotic,




FIG 1 Indomethacin worsens the effects of *C. difficile* infection in mice. (A) C57BL/6 mice were treated with cefoperazone for 5 days followed by 2 days of recovery and then challenged by gavage with 1×10^4 spores of NAP1 strain M7404. Animals received 2 doses of 10 mg/kg of body weight of indomethacin by gavage daily as indicated by the top arrows. (B) Representative picture illustrating the macroscopic effects of the different treatments in the cecum. Indo, indomethacin; Abx, antibiotic; *C. diff.*, *C. difficile*. (C to E) Mice were monitored for survival (Kaplan-Meier curve) (C), weight loss (D), and histopathologic severity of colitis (E) ($n = 13$ to 15/group). (F and G) *C. difficile* bacterial burden was evaluated in the ceca of 12 mice/group (F) and total aerobic bacterial burden plus anaerobic bacterial burden in the liver of 5 mice/group (G) also at day 3 after infection, with the discontinuous line indicating the limit of detection. Path., pathology. ** $P < 0.01$ (by log rank [Mantel-Cox] test for survival [panel C] and by unpaired t test for weights [panel D]); * $P < 0.05$ (1-way analysis of variance [ANOVA] test for histopathological scores [panel E]); ** $P < 0.01$ (Wilcoxon test with Bonferroni correction [panel G]). I, indomethacin; A, antibiotic.


cefoperazone (Fig. 1A). This brief indomethacin treatment prior to CDI dramatically decreased cecum size and increased the mortality rate from 20% to 80% (Fig. 1C) but did not significantly impact weight loss (Fig. 1D). Mice pretreated with indomethacin and infected with *C. difficile* also displayed histopathological evidence of more-severe

cecal tissue damage compared to mice infected with *C. difficile* that were not exposed to the drug (Fig. 1E). Indomethacin-exposed and infected mice exhibited no change in the burden of *C. difficile* in the cecum (Fig. 1F), but their livers harbored significantly greater loads of mixed aerobic and anaerobic bacteria (Fig. 1G), suggesting that indomethacin pretreatment compromised intestinal barrier function during CDI and fostered microbiota translocation to the liver.

Indomethacin alters the proportions of neutrophils and CD4⁺ T cells in mucosal-associated tissues during *C. difficile* infection. The mucosal immune response is an important factor in the clearance of and the pathology associated with CDI (10, 24–27). NSAIDs can disturb immune homeostasis within the gastrointestinal mucosa (28) and have been used to trigger immune-mediated colitis in mice (29). We determined the extent to which indomethacin altered immune cell populations in and around the gastrointestinal tract during CDI. Mice were euthanized by day 3 after infection, and cells from the peritoneal cavity, mesenteric lymph nodes (mLN), and colonic lamina propria (cLP) were processed for flow cytometry analysis. CDI provoked an increase of neutrophil and CD4⁺ T cell numbers across all three compartments (Fig. 2). Focusing on the differences caused by indomethacin exposure prior to CDI, we found that neutrophils levels were significantly increased in the peritoneal cavity compared to those seen with CDI alone. This was paralleled by a similar overall trend in the mLN and colonic lamina propria (Fig. 2B). On the other hand, numbers CD4⁺ T cells were slightly decreased in the mLN but were increased in the cLP (Fig. 2C), possibly due to selective migration and/or proliferation in inflamed sites. Considering that IL-17 has been implicated in driving the neutrophilic inflammatory response to CDI (88) and that Th17 cells and innate lymphoid cells, type 3 (ILC3), are major sources of IL-17 during inflammatory responses, we evaluated the combined effects of indomethacin and CDI on these populations. Interestingly, higher numbers of CD4⁺ ROR γ t⁺ (Th17) cells were found in the cLP but not in the mLN (Fig. 2D). CDI also induced a modest expansion of ILC3 cell numbers in the cLP, but there were no significant alterations due to indomethacin pretreatment (Fig. 2E). These data demonstrate that indomethacin pretreatment exacerbates neutrophilic and Th17-type immune responses in the intestinal milieu to CDI in the mouse.

Indomethacin dysregulates the expression of genes involved in prostaglandin metabolism and inflammatory peptides during CDI. CDI induces extensive transcriptional changes in the intestines that generally result in protective responses that restrain bacterial spread and mitigate induced intestinal epithelial pathology (3, 30). To examine the impact of indomethacin on this response, we interrogated transcriptional changes related to inflammatory responses in the cecum following indomethacin pretreatment followed by CDI using a panel of inflammatory markers (NanoString nCounter) that encompassed 254 transcripts. After curating the processed raw data to remove false positives/negatives, to normalize the data, and to filter for internal coherence with 6 housekeeping genes, we obtained mRNA values for 168 genes and generated a list of genes significantly altered upon exposure to each treatment compared to the antibiotic-treatment-alone group. We noted significant alterations, both positive and negative, in the inflammatory gene transcriptome of the cecum in mice infected with *C. difficile* following brief indomethacin exposure compared with *C. difficile*-inoculated mice that were not treated with the NSAID (Fig. 3B to D). Notably, indomethacin pretreatment followed by CDI significantly upregulated several genes involved in innate immune cell activation and recruitment such as *Il1b*, *Cxcl3*, *Csf3*, and *Cxcl1* and downregulated *Cd4*, *Tlr5*, and *Tgfb2* (Fig. 3C and D).

To further characterize the impact of NSAIDs on the immune response during CDI, we explored the impact of indomethacin on intrinsic mechanisms of host defense in the gastrointestinal tract. Specifically, we focused on the Gram-positive selective antimicrobial peptide REG3 γ and on mucin, two host intestinal defense factors that have been shown to be important for the control of gastrointestinal infections (31). We confirmed by quantitative reverse transcription-PCR (qRT-PCR) that CDI upregulated *Reg3g* transcription whereas *Muc2* transcript levels were not significantly altered fol-



lowing indomethacin treatment (Fig. 3E). To evaluate if PGE₂ synthesis and signaling were altered due to infection or indomethacin treatment, we analyzed the expression of genes encoding PGE₂ receptors and the enzymes involved in PGE₂ metabolism. The transcription of PGE₂ receptor gene *Ptger4* was severely suppressed upon CDI, but indomethacin did not significantly exacerbate the suppression (Fig. 3F). Infection with *C. difficile* suppressed colonic expression of the *Ptgs1* and *Ptgs2* genes, encoding COX-1 and COX-2, respectively (Fig. 3G). Notably, indomethacin pretreatment prevented this downmodulation and simultaneously induced the expression of the *Ptges* gene, which encodes an inducible synthase for PGE₂ (Fig. 3G). What is more, indomethacin further reduced expression of the gene encoding PGE₂-inactivating enzyme 15-hydroxyprostaglandin dehydrogenase (*Hpgd* gene; Fig. 3G). This selective inhibition of *Ptgs2* transcription, together with inhibition of *Hpgd* and enhancement of *Ptges*, is consistent with the paradoxical increase in PGE₂ concentrations that we observed at 72 h after infection in the supernatant of colon explants from mice treated in the same manner (Fig. 3H). Together, these data demonstrate that indomethacin pretreatment increases innate immune cell activation and recruitment while also leading to PG dysregulation.

Indomethacin increases intestinal inflammation by upregulating a combination of myeloid cell recruitment and response in the cecum. Following the observation that indomethacin pretreatment significantly altered cellular and transcriptional immune responses during CDI, we sought to determine the impact of this drug on tissue-level inflammatory protein expression during infection. Infected mice (exposed or not exposed to indomethacin) were euthanized, and ceca were harvested at day 3 post-CDI. Whole-tissue homogenates were used to measure the concentration of a panel of inflammation-related proteins and were normalized to total protein content per cecum (Fig. 4). The protein levels observed largely supported the transcriptomics results from our previous studies, confirming what has already been reported for CDI regarding IL-1 β and immune mononuclear cell recruitment and activation proteins such as CCL3, CXCL2, and CCL4. Interestingly, class II-6 cytokines (IL-6, leukemia inhibitory factor [LIF]) were among those whose numbers were most enhanced by indomethacin pretreatment, consistent with what has been found in humans infected with *C. difficile* (25, 32, 33). Together with the increase in IL-1 β , and consistent with the results reported above showing enhanced Th17 responses, these data imply that an exacerbated IL-17A-related response caused by indomethacin had occurred. In contrast, some type-1-associated inflammatory molecules such as IL-12p40 were down-regulated by indomethacin pretreatment.

Indomethacin perturbs colonic epithelial cell junctions of *C. difficile*-infected mice. The observations of the increased bacterial translocation (Fig. 1G), together with the increased local PGE₂ levels (Fig. 3H) and enhancement of numbers of inflammatory molecules (Fig. 4), led us to investigate whether the integrity of the intestinal epithelial barrier was compromised due to indomethacin pretreatment during CDI. We assessed the impact of indomethacin on the integrity of colonic epithelial junctions of *C. difficile*-infected mice via transmission electron microscopy and immunofluorescence staining of tight junction (TJ) proteins and TJ-associated proteins. Intestinal epithelial cells (IECs) of uninfected mice, cefoperazone-treated and uninfected mice, and cefoperazone-and-indomethacin-pretreated mice had uniform microvilli and intact cell

FIG 2 Indomethacin alters the proportions of neutrophils and CD4⁺ T cells in mucosa-associated tissues during CDI. Mice were treated as previously described and were euthanized 3 days after infection. The colon lamina propria (Colon LP), mesenteric lymph nodes (mLN), and peritoneal cavity (Per.Cav.) were collected for analysis by flow cytometry ($n = 8$ to 10/group). (A) Representative flow plots from day 3 (d3) CDI mice subjected to infection but not treated with indomethacin, depicting the gating used to identify neutrophils (Lin⁺ Ly6G⁺), CD4⁺ T cells (Lin⁻ CD4⁺), and ILC group 3 cells (Lin⁻ Ly6G⁻ CD4⁻ ROR γ t⁺) in different organs. Colonic LP, colon lamina propria; Mes. LN, mesenteric lymph nodes. (B and C) Neutrophil (Neutr.) numbers ($\times 10^6$) (B) and CD4⁺ T cell numbers ($\times 10^6$) (C). (D and E) Quantification of results of the analysis of mLN and cLP CD4⁺ ROR γ t⁺ Th17 cells (D) and ILC type 3 (Lin⁻ CD3 ϵ ⁻ ROR γ t⁺) cells (E). The horizontal middle line in each column represents the average. One-way analysis of variance (ANOVA) with Turkey's correction was used to evaluate significant differences among all groups. *, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$.




FIG 3 Prostaglandin inhibition by indomethacin inhibits an intestinal protective PGE₂-mediated response to *Clostridium difficile* and induces damage driven by innate immune cells. (A) Representative clustering showing relative mRNA expression levels comparing (Continued on next page)




FIG 4 Indomethacin treatment enhances the inflammatory milieu in ceca of mice infected with *C. difficile*. Mice were treated as described for Fig. 3 and 4 and their ceca collected at day 3 after infection. (A) Protein expression levels in homogenates from individual ceca were measured by Luminex assay and plotted on a log₂ scale. *n* = 7 to 8/group. All values are provided in picograms of protein/cecum protein content. VEGF, vascular endothelial growth factor receptor. (B) Selected proinflammatory cytokines and myeloid cell-recruiting chemokines plotted to depict the range of variation. Filled triangles in the A + I + CDI group are color-coded to match individual samples.

junctions similar to those seen with mock-treated mice (Fig. 5A). *C. difficile* infection resulted in effacement of microvilli of intestinal epithelial cells but did not appear to cause gross structural alterations of the cell junctions. In contrast, indomethacin pretreatment of *C. difficile*-infected mice triggered striking intestinal epithelial cell separation at the region of the TJs.

TJ complexes containing membrane-anchored occludin, claudins, and junctional adhesion molecules (JAMs) attach to the perijunctional actomyosin ring via adaptor proteins such as zona occludens 1 (ZO1). Consistent with the intact cell junctions observed in IECs of uninfected mice, occludin and ZO1 localized at the apex of lateral cell junctions (Fig. 5B and C). In contrast, CDI resulted in occludin relocation to the cytoplasm of epithelial cells. ZO1 redistribution to the cytoplasm, however, was observed only in *C. difficile*-infected mice that were previously treated with indomethacin

FIG 3 Legend (Continued)

(x axis) the groups that received CDI alone (red) to those that received control cefoperazone only (blue) from one experiment performed with *n* = 7/group at day 3 of treatment. (B) Venn diagram depicting overlap in gene upregulation and downregulation upon CDI or CDI+ indomethacin pretreatment compared to control mice. The size of each circle is proportional to number of genes. (C) Volcano plot of CDI+ indomethacin treatment results versus control results. Red dots in the volcano plots represent significantly differently expressed genes that were either underexpressed or overexpressed. The horizontal line represents the adjusted *P* value cutoff of 0.1; the vertical lines represent fold cutoff values of 0.5 and 2. The red dots represent the winner genes. (D) Summary of gene data, depicting the highest fold differences in upregulation (red) and downregulation (blue) in comparisons of the CDI+ indomethacin group to the CDI-alone group. Data from panels B to D were pooled from 2 experiments with *n* = 11 to 12 samples/group. (E to G) Relative mRNA expression levels of intestinal markers of inflammation and protection *Reg3g* and *Muc2* (E), the degrading PGE₂ catabolic enzyme 15-PGHD (*Hpgd*) and PGE₂ receptor EP4 (*ptger4*) (F), and the inducible enzymes controlling PGE₂ metabolism COX2 and mPGES (*Ptgs2* and *Ptgs*) (G). Ceca from mice undergoing treatment were used to obtain mRNA, generate cDNA, and perform RT-PCR at day 3 post-CDI from 8 mice/group pooled from 2 experiments. *, *P* < 0.05; **, *P* < 0.01 (1-way ANOVA). (H) PGE₂ concentration (in nanograms per milligram of tissue) in the supernatants of colon explants cultured for 12 h from the mice in the indicated treated groups (*n* = 4 to 5/group). **, *P* < 0.05; ***, *P* < 0.01 (heteroscedastic unpaired *t* test).




FIG 5 Indomethacin promotes relocalization of TJ-associated protein ZO1 and perturbs colonic epithelial cell junctions of *C. difficile*-infected mice. (A) Transmission electron micrographs showing lateral views of colonic mucosa from untreated control mice (Mock) or mice treated with the following: cefoperazone alone (Abx); cefoperazone and indomethacin (Abx + Indo); cefoperazone and *C. difficile* (Abx + CD); or cefoperazone, indomethacin, and *C. difficile* (Abx + Indo + CD). Arrows point to intact tight junctions (TJ). Red arrowheads point to TJ unzipping or separation. (B and C) Mouse colonic tissues from the groups described above were stained for TJ-protein occludin (B) and TJ-associated protein ZO1 (C). Occludin and ZO1 stain are pseudocolored in red. DAPI (blue) was used to stain DNA. Yellow arrowheads and white arrowheads indicate cytoplasmic relocalization of occludin and ZO1, respectively (see also Fig. S1).

(see Fig. S1 in the supplemental material). Collectively, our data suggest that indomethacin acts synergistically with *C. difficile* to alter the localization of occludin and ZO1 and to perturb the TJ integrity of intestinal epithelial cells *in vivo*.

Indomethacin alters the intestinal microbiota composition without further reducing microbial community diversity after antibiotic treatment. The composition of the gut microbiota has a profound impact on the manifestation and clearance of CDI, as well as on the virulence of *C. difficile* and on the outcome of disease (34, 35). There is also evidence suggesting prominent off-target effects of pharmaceutical agents, such as NSAIDs, on the gut microbiota and on gastrointestinal health (21, 36). To examine the impact of indomethacin on the murine gut microbiota, mice were treated with a 2-day course of indomethacin and the microbial community was subsequently surveyed using 16S rRNA gene sequencing. At 1 day posttreatment, mice given indomethacin showed no significant alteration in α -diversity (Fig. S2) but exhibited a significant shift in community structure compared to untreated mice ($P < 0.001$




FIG 6 Indomethacin treatment alters the gut microbiota. (A) Nonmetric multidimensional scaling (NMSD) ordination showing β -diversity as measured by Yue and Clayton's measure of dissimilarity ($\theta_{y,c}$) on day 1 post-indomethacin treatment. The significance of results of comparisons between baseline (black) and indomethacin-treated (blue) samples was determined using analysis of molecular variance (AMOVA) ($P < 0.001$). (B) Differentially abundant taxa in baseline and indomethacin-treated animals ranked by effect size. (C) Dynamics of recovery of differentially abundant taxa over an 11-day time course. Sample sizes: column B (baseline microbiota pretreatment), $n = 13$; column d1, $n = 14$; column d2, $n = 11$; column d5, $n = 4$; column d6, $n = 6$; column d11, $n = 6$. (D) Shannon diversity index for untreated (baseline; black), cefoperazone-treated (gray), or cefoperazone-and-indomethacin-treated (red) mice (see also Fig. S2). (E and F) Dynamics of *Paenibacillus* (E) and *Akkermansia* (F) relative abundances following cefoperazone treatment (gray) and cefoperazone-plus-indomethacin treatment (red) (see also Fig. S3).

[analysis of molecular variance {AMOVA}] (Fig. 6A). To characterize differentially abundant taxa in indomethacin-treated mice, we utilized the biomarker discovery algorithm LEfSe (linear discriminant analysis [LDA] effect size). Indomethacin treatment was associated with an enrichment in numbers of operational taxonomic units (OTUs)

affiliated with the *Bacteroides* (OTU 1), *Akkermansia* (OTU 4), and *Parasutterella* (OTU 17) genera and with the *Porphyromonadaceae* (OTU 14) family (Fig. 6B and C). Moreover, we observed a significant decrease in OTUs affiliated with the *Turicibacter* (OTU 18) genus and *Porphyromonadaceae* (OTU 5) family following indomethacin treatment (Fig. 6B and C). To examine the longitudinal impact of indomethacin on the murine gut microbiota, we collected samples periodically for 11 days following administration of indomethacin. We observed significant differences in community structure at up to 2 days following administration of indomethacin treatment, and a significant enrichment of *Bacteroides* (OTU 1) could be detected as much as 11 days following treatment with indomethacin (Fig. 6C). Next, to determine how indomethacin may impact the microbiota in the context of antibiotic treatment, mice were again exposed to indomethacin for 2 days following 5 days of cefoperazone (0.5 mg/ml) treatment. Although cefoperazone treatment dramatically reduced the overall level of community α -diversity in all mice, we detected significant alterations in community structure associated with cotreatment with indomethacin and cefoperazone that could be observed at 11 days posttreatment (Fig. 6D; see also Fig. S3). Initial differences in microbial community structure were driven by a significant bloom in *Paenibacillus* (OTU 11), while *Akkermansia* (OTU 6) was significantly enriched in mice treated with indomethacin and cefoperazone on day 11 posttreatment (Fig. 6E and F). Together, these data suggest that indomethacin has a marked effect on the structure of the gut microbiota and that these off-target effects likely contribute to disease exacerbation during CDI.

DISCUSSION

CDI is the most commonly diagnosed cause of antibiotic-associated diarrhea and has surpassed methicillin-resistant *Staphylococcus aureus* as the most common health care associated infection in many U.S. hospitals (37). Nearly 30,000 people die each year in the United States from CDI (38). A major challenge of CDI is recurrence, which can impact 20% to 30% of patients and is associated with an increased risk of death (4, 39). One of the most promising treatments for CDI is fecal microbiota transplantation (FMT), which is estimated to be >80% effective in most studies (40, 41). However, problems with standardization and availability and putative risks from FMT have made this form of therapy suboptimal (42). There continues to be a demand for effective approaches to limit CDI severity and to understand complications arising from the synergy of CDI with intestinal immune responses and with the drugs used to limit damaging inflammatory effects.

The NSAIDs are among the most commonly prescribed drugs in the United States, with more than 98 million prescriptions filled annually (15), and an estimated 29 million Americans use over-the-counter NSAIDs per year (43). As they prevent synthesis of endogenous PGs, NSAIDs can adversely affect intestinal health. Results from epidemiological studies, underscored by a recent meta-analysis (11), have revealed an association between CDI risk and the use of NSAIDs. The plausibility of a link between NSAID use and CDI is bolstered by the association between NSAID use and flare-ups of inflammatory bowel disease and the occasional occurrence of NSAID-induced colitis (44–47). Recent mouse studies have established that concomitant NSAID use exacerbates active CDI (12).

Animal and human studies suggest that CDI induces local and systemic increases in PGs, including PGE₂ (48). Prostaglandin E₂ is one of the most common and best-characterized PGs and has long been known to have major effects on gastrointestinal health (49–52). COX-1-dependent production of PGE₂ is gastroprotective, explaining why chronic NSAID use is associated with stomach ulcers and why such ulcers can be prevented by administering the FDA-approved oral PGE analogue misoprostol to NSAID-treated patients (53). In addition, endogenous PGE₂ production prevents gut epithelial cell death and promotes colonic tumor growth by directly inducing tumor epithelial cell proliferation, survival, and migration invasion (53–55). It is also possible that PGE₂ modulates disease through alteration of the microbiome, as NSAIDs have

been implicated as potentially disrupting the gut microbiome (21, 56). Additionally, PGE₂ functions as a key inflammatory signal that can regulate certain immune responses, with its local levels being tightly regulated during the trigger of but also the resolution of inflammatory processes (57–59). Some of the best-known functions of PGE₂ are indeed its role in intestinal inflammation and cancer and its impact on the immune system (19). Paradoxically, we observed that pretreatment with the COX inhibitor indomethacin caused a dysregulation of PG metabolism that led to increased PGE₂ production upon CDI. This heightened PGE₂ production might represent a “rebound” effect following temporary exposure to indomethacin prior to infection, since continued indomethacin dosing throughout infection was recently shown to suppress PGE₂ production (12). This exaggerated PGE₂ response was associated with elevated levels of intestinal inflammatory cytokines, monocyte and neutrophil recruitment, partial dismantling of the intestinal epithelial cell’s tight junctions, and a specific disturbed microbiota composition. Interestingly, this is highly consistent with several studies that reported a protective role for PGE₂ in inducing an orchestrated tolerance response that involves innate immune cells such as ILC3 cells, neutrophils, and macrophages (58, 60, 61).

Immune protection against *C. difficile* challenge seems function independently of the presence of CD4⁺ cells, anti-toxin IgG, and plgR (62), but it strongly relies on rapid and effective myeloid cell responses (9, 38, 63). Cells of the immune system can exert critical roles in controlling bacterial pathogen damage and intestinal health through production of damaging or protective cytokines by T cells or innate lymphoid cells (ILCs) (64, 65). Production of gamma interferon (IFN- γ) by T cells and neutrophils has a role in protection against CDI (66, 67), and the associated production of IL-12 by innate cells upon CDI can have a strong positive-feedback effect on IFN- γ production in this context. The role of IL-17 cytokines and of their cellular sources is more controversial, as they can induce damage but can also trigger intestinal repair processes and maintain barrier integrity (68, 69). Perturbation of the microbiota induced by antibiotic treatment can also cause an imbalance of protective Treg/Th17 ratios (70). ILCs are, however, critical for controlling the acute response induced by CDI. In contrast to Rag1^{-/-} mice, Rag2^{-/-} Il2r γ ^{-/-} mice rapidly succumb to CDI. While ILC3 cells display a limited role in resistance, loss of IFN- γ -expressing ILC1s in Rag1^{-/-} mice increased susceptibility (7). The contribution to CDI pathogenesis by other highly relevant cytokines such as IL-23 and IL-22 provided by innate immune cells strongly depends on context (24, 25, 38, 71–73). In our studies, we found that indomethacin pretreatment prior to CDI increased local levels of chemokines that induce recruitment of inflammatory myeloid cells such as CXCL2, CCL3, and CCL4, with a concomitant increase in numbers of circulating and local neutrophils, while type 3 ILC numbers were unaltered. Also, in coordination with the increased levels of intestinal IL-6 and IL-1 β , higher total numbers of CD4⁺ cells and CD4⁺ ROR γ t⁺ cells were found in the colonic lamina propria but not the draining mesenteric lymph nodes.

Intestinal epithelial cells constitute the main barrier against infectious agents colonizing the gastrointestinal tract. Cell junctional complexes, notably, the tight junctions, regulate paracellular permeability and restrict the translocation of luminal microbes and microbial products across the epithelial monolayer (74). Displacement of occludin, but not ZO-1, from the junctions of mouse colonic epithelial cells during CDI did not manifest as gross morphological changes of TJ regions during EM visualization. This is reminiscent of the alterations seen in anti-CD3-treated mice or tumor necrosis factor alpha (TNF- α)-treated mice and is consistent with the view that occludin is a regulator, rather than a key structural component, of TJs (75). However, indomethacin pretreatment with CDI redistributed both occludin and ZO-1 to the cytosol, and electron micrographs revealed a concomitant loss of TJ interactions. These changes are expected to increase paracellular permeability and promote bacterial translocation and could explain the observed increase in bacterial burden in the livers of indomethacin-treated, *C. difficile*-infected animals.

Induction of severe colitis upon CDI is subordinated to alterations in the microbiota

caused by antibiotic administration that lead to dismantling of colonization resistance (5, 34, 38, 76, 77). Interestingly, recent studies have begun to highlight previously underappreciated and potentially detrimental effects of pharmaceutical drugs, such as NSAIDs, on the gut microbiota (21, 36). We observed that indomethacin did not cause an alteration of the microbial α -diversity but did induce significant alterations in microbiota structure that lead to an enrichment of *Bacteroides*, *Akkermansia*, *Porphyromonadaceae*, and *Parasutterella* populations and to a decrease in *Turicibacter* and *Porphyromonadaceae* populations. Interestingly, increases in *Bacteroides* and *Akkermansia* populations have been reported to have occurred in association with inflammatory bowel disease and other infections (78–81). Furthermore, *Turicibacter* has been shown in several studies to be associated with colonization resistance to *C. difficile* (6, 82). Thus, indomethacin-mediated alterations in the microbiota may have a profound impact on the manifestation and severity of CDI. Interestingly, when the microbiota α -diversity was severely reduced by antibiotic treatment, we found that *Paenibacillus* and *Akkermansia* populations expanded in mice pretreated with indomethacin. The role of *Paenibacillus* in the pathology of CDI is unknown at present, and further investigation is warranted.

Injury to intestinal epithelial barriers and microbial translocation can lead to a systemic response that mimics some aspects of sepsis and unveils a massive release of inflammatory cytokines, such as IL-1 β , that increases neutrophil and macrophage recruitment and activation (25). It is still unclear how the innate and adaptive arms of the immune response coordinate during CDI, especially in situations such as the one we present with pretreatment with indomethacin. In such circumstances, it is important that type 3 ILCs can dysregulate adaptive immune CD4⁺ cell responses against commensal bacteria but that this ILC-mediated regulation of adaptive immune cells occurs independently of IL-17A, IL-22, or IL-23 but is dependent on antigen presentation (83). Additionally, administration of antibiotics alone can promote inflammation through goblet cell-mediated translocation of native colonic microbiota in mice (84), but CDI induces significant goblet cell loss (85), which would have a countering effect on bacterial translocation under experimental conditions such as those described in this work.

Our results highlight the capacity of a short-term oral dose of the NSAID indomethacin to cause an imbalance in PG production and to disrupt the intestinal barrier to allow bacterial entrance in the bloodstream. These effects are paralleled by a specific disarrangement of the intestinal microbiota and by dysregulated inflammatory and immune responses that lead to increase pathological damage and finally unfold in an increased mortality rate. Our results call for caution in the use of NSAIDs in the context of *C. difficile* infections but also potentially when other intestinal pathogens or insults co-occur with acute inflammatory events that affect PG balances. Moreover, we also highlight how a temporary modification of a set of key inflammatory mediators such as PGs in the host can lead to significant perturbations to the resident gut microbiota. We believe that this unique combination of effects caused by indomethacin and CDI in the host and their microbiota could represent a generalized mechanism that leads to increased intestinal damage and complications when NSAIDs, or other drugs that alter key inflammatory molecules with pleiotropic effects, are used. Given the common application of NSAIDs to treat diverse inflammatory conditions, together with the disturbances in microbiota diversity and the rates of increased incidence of CDI in developed countries, the results of these studies warrant future follow-up studies in humans.

MATERIALS AND METHODS

Experimental animals and infection model. All mice used in this study were obtained from Jackson Laboratories and were C57BL/6J females that were 6 weeks of age at arrival. Mice were given 2 weeks to adapt to the new facilities and avoid stress-associated responses and to allow adaptation to the in-house conditions. Mice were given cefoperazone at 0.5 mg/ml in drinking water *ad libitum* for 5 days prior to treatment with indomethacin (Cayman Chemical) at 10 mg/kg of body weight or with vehicle (phosphate-buffered saline [PBS]) for 2 consecutive days by oral gavage and then infected with 1×10^4

spores of *Clostridium difficile* (NAP1/BI/027 strain M7404; 89) resuspended in PBS by oral gavage or were left noninfected. Noninfected mice received only cefoperazone and afterward only vehicle by oral gavage at the same time points. For some experiments, untreated mice were used to obtain unaltered cecal microbiota.

mRNA isolation, expression analysis and qRT-PCR. After bulk RNA was isolated from tissues with TRIzol (Life Technologies) following the manufacturer's instructions, a Qiagen RNeasy Plus minikit was used to further purify mRNA for downstream analysis. mRNA expression was evaluated either by the use of nSolver inflammation panel mouse v2 from NanoString (https://www.nanostring.com/application/files/9414/9556/0025/LBL-10402-01_nCounter_Mouse_Inflammation_V2_Panel_Gene_List.xlsx) directly on mRNA samples or by qRT-PCR performed using an Applied Biosystems TaqMan amplification system after cDNA generation using a SuperScript VILO cDNA synthesis kit (Invitrogen). Data generated by NanoString technologies for mRNA quantification (the full gene list is available at https://www.nanostring.com/download_file/view/409/3778) were analyzed after generating raw counts that were produced using R version 3.3.2 (<https://www.R-project.org/>) for Fig. 3A to D. The count data produced by the n-Counter Digital Analyzer for each of the two experiments were normalized using positive controls (geometric mean method) and housekeeping genes (geometric mean method). The two sets of data were then normalized together to be combined and analyzed together. After exclusion of one Indo-plus-CDI sample (because that mouse was confirmed not to have been infected with CDI by cecal content culture), the final normalized data set included 11 control samples and 11 Indo-treated, 12 CDI-treated, and 11 CDI-plus-Indo-treated samples. A gene was included in the analyses if its counts were above the maximum count seen with the negative control in at least 5 samples in any group. Of 248 genes, 161 were included in the subsequent analysis. For each included gene, a linear regression model was fitted with "group" as the independent variable of interest. Robust standard errors were estimated using the Huber-White method for the coefficients. The mean of the expression levels determined for each group was used to calculate the fold change between groups. *P* values for testing the mean difference between groups were adjusted using the Benjamini & Hochberg method. Volcano plots were generated using the fold change values and adjusted *P* values. A gene was selected as a "winner" gene if the adjusted *P* value was lower than 0.1 and the fold change value was higher than 2 or lower than 0.5. A heat map of the winner genes was produced to visualize the clustering of samples and genes. qRT-PCRs and data quantification and analysis were performed using an Applied Biosystems 7300 Real-Time PCR system and the following TaqMan primers: Reg3g (Mm00441127_m1), Muc2 (Mm01276696_m1), Ptger2 (Mm004360516_m1), Ptger4 (Mm004360513_m1), Ptgs1 (Mm00477214_m1), Ptgs2 (Mm00478374_m1), Ptges (Mm00452105_m1), Hpgd (Mm00515121_m1), and Gapdh (Mm99999915_g1).

Bacterial burden in mouse organs. Liver was collected from the mouse with sanitized instruments and immediately placed in 1 ml of PBS in a 12-well plate. After the tissue was minced with scissors, 20 ml of the supernatant was drawn off and serially diluted. Dilutions were plated on sheep blood agar plates under aerobic and anaerobic conditions. After 24 h, the plates were collected and CFU levels were calculated and normalized to the weight of the liver. Cecum was also collected using sanitized instruments, and contents were expelled by applying pressure to the organ with a scalpel. The contents were then collected and put into a 1.5-ml tube. The weight of the contents was recorded; PBS was added; and the slurry was subjected to vortex mixing, serially diluted, and plated onto sheep blood agar plates (Anaerobe Systems). After 24 h, CFU counts were performed and the data were normalized to the weight of each sample.

Tissue protein quantification, PGE₂ measures, and multiplex analysis. Total cecum protein was isolated from caeca prewashed with ice-cold PBS, homogenized by the use of a tissue shredder (Tissue-miser), and then centrifuged for 3 min at 8,600 × *g*. Supernatants of these preparations were submitted for Luminex analysis of the provided analytes using x-map technology via the use of a MagPix system in combination with multiplex kits from Millipore Sigma. Total tissue protein content was quantified by detergent-compatible (DC) assay. Data were analyzed with GraphPad Prism 6.0, and heat maps were generated using Morpheus software from the Broad Institute (<https://software.broadinstitute.org/morpheus/>). Supernatants of colon explants were incubated for 12 h in RPMI medium supplemented with 10% fetal calf serum (FCS) and GlutaMAX in an incubator at 37°C and 5% CO₂ saturation and were used to measure PGE₂ concentrations with a PGE₂ enzyme-linked immunosorbent assay (ELISA) kit (Cayman Chemical) following manufacturer's instructions.

Flow cytometry. Cell suspensions from the mesenteric lymph nodes, peritoneal lavage fluid, and colon lamina propria were obtained from euthanized mice at the indicated time points. Cell suspensions were incubated with Fc-block for 15 min on ice and then surface stained with a cocktail containing monoclonal anti-mouse antibodies, including anti-CD19 (1D3), CD8a (5H10-1), anti-CD49b (DX5), anti-CD11b (M1/70), anti-CD11c (N418), and anti-CD196 (x29-2I.17) from BioLegend as well as anti-CD4 (RM4-5) and anti-Ly6G (1A8) from BD. After 30 min of incubation on ice, cells were washed, fixed, and permeabilized using a FoxP3 Fix/Perm buffer kit from eBioscience/Thermo Fisher, and intracellular staining for RORγt (clone Q31-378) was performed as a last step. Flow cytometry data were obtained with BD FACSDiva 7.0 software and .fcs 3.0 files analyzed with FlowJo software.

Electron and immunofluorescence microscopy. Colonic tissue samples were fixed and stored in Karnovsky's solution (4% paraformaldehyde–PBS [pH 7.4]–1% glutaraldehyde) for at least 24 h at 4°C. Samples were neutralized with 125 mM glycine–PBS, postfixed in 1% osmium tetroxide, and sequentially dehydrated with 15%, 30%, 50%, 70%, 90%, and 100% ethanol. Samples were then infiltrated with Spurr's resin (Electron Microscopy Sciences, Hatfield, PA). Ultrathin sections were contrasted using 2% uranyl acetate, followed by Reynold's lead citrate, and were visualized with a FEI Tecnai Spirit transmission

electron microscope (FEI, Hillsboro, OR) equipped with an Advanced Microscopy Techniques (AMT) charge-coupled-device (CCD) camera and AMT Image Capture Engine V602 software (Advanced Microscopy Techniques, Woburn, MA).

For immunofluorescence microscopy, tissue samples were frozen in OCT embedding medium (Tissue-Tek; Sakura Finetek, Torrance, CA) and stored at -80°C . OCT-mounted tissue samples were sectioned at $3\ \mu\text{m}$ thickness and fixed in 4% paraformaldehyde–PBS (pH 7.4) for 20 min at room temperature. Samples were washed with PBS, permeabilized with 0.2% Triton X-100–PBS, quenched with 50 mM NH_4Cl –PBS, and then blocked with 5% IgG-free bovine serum albumin (BSA)–PBS. Primary antibodies used were 1:50 dilutions of rabbit anti-occludin and rabbit anti-ZO1 (Abcam, Cambridge, MA). Samples were incubated with primary antisera overnight at 4°C and then washed three times with 1% IgG-free BSA–PBS. Secondary antibodies (Alexa Fluor 555-conjugated anti-rabbit IgG) were added at $8\ \mu\text{g}/\text{ml}$ in 5% IgG-free BSA for 1 h. Samples were washed with PBS, stained with 4,6-diamidino-2-phenylindole (DAPI), and mounted in ProLong Diamond antifade reagent (Thermo Fisher Scientific, Waltham, MA). Images were captured using a DeltaVision Elite deconvolution microscope (GE Healthcare, Pittsburgh, PA) equipped with an Olympus $100\times/1.40$ oil objective, immersion oil ($n = 1.516$), and GE Healthcare Software Version 6.5.2. ImageJ 1.51j8 (National Institutes of Health, Bethesda, MA) was used to merge and pseudocolor images.

Colon histology and pathology scoring. Colons from experimental mice were collected at day 3 postinfection and then flushed with cold PBS, opened longitudinally, and rolled to generate Swiss rolls. The colon rolls were fixed for 5 days in 10% buffered Formalin phosphate and then transferred to 70% ethanol for 7 days. After that, the Swiss rolls were used to generate paraffin blocks that were stained with hematoxylin and eosin (H&E) and scored for the degree of injuries as described by Theriot et al. (74).

DNA extraction, 16S rRNA gene sequencing, and gut microbiota analyses. Fresh fecal samples were collected from individual mice prior to (baseline) and following treatment with cefoperazone, indomethacin, or a combination of cefoperazone and indomethacin. In a subset of mice ($n = 6/\text{group}$), fecal samples were collected for the time course of a posttreatment 11-day recovery period. Following collection, fecal samples were immediately put on ice and subsequently frozen for storage at -20°C . Microbial genomic DNA was extracted using a 96-well PowerSoil DNA isolation kit (Qiagen). For each sample, the V4 region of the bacterial 16S rRNA gene was amplified and sequenced using an Illumina MiSeq Sequencing platform as described elsewhere (86). Sequences were curated using the mothur software package (v1.40.3) as previously described (6, 86, 87). Briefly, the workflow that we used included generating contigs with paired-end reads, filtering low-quality sequences, aligning the resulting sequences to the SILVA 16S rRNA sequence database, and removing any chimeric sequences flagged by UCHIME. Following curation, we obtained between 9 and 83,525 sequences per sample (median = 13,161.5), with a median length of 253 bp. To minimize the impact of uneven sampling, the number of sequences in each sample was rarefied to 4,200. Sequences were clustered into OTUs based on a 3% distance cutoff calculated using the OptiClust algorithm. All sequences were classified using the Ribosomal Database Project training set (version 16), and OTUs were assigned a taxonomic classification using a naive Bayesian classifier. Significantly altered OTUs for each group were selected using the biomarker discovery algorithm LEfSe (linear discriminant analysis [LDA] effect size) in mothur (90). α -Diversity was calculated using the Shannon diversity index, and β -diversity was calculated using the θ_{VC} distance metric with OTU frequency data. Pairwise analysis of molecular variance (AMOVA) was used to test the statistical significance of the results of comparisons between treatment groups using the θ_{VC} distance metric.

Accession number(s). FASTQ sequence data obtained in this study have been deposited to the Sequence Read Archive (SRA) at NCBI under accession number [SRP152292](https://doi.org/10.1128/mBio.02282-18).

SUPPLEMENTAL MATERIAL

Supplemental material for this article may be found at <https://doi.org/10.1128/mBio.02282-18>.

FIG S1, TIF file, 3.4 MB.

FIG S2, TIF file, 0.1 MB.

FIG S3, TIF file, 0.3 MB.

ACKNOWLEDGMENTS

D.M.A., D.M., and J.P.Z. designed the research and analyzed the data. D.M., J.P.Z., B.T., L.K., J.L.R., L.M.R., and M.K.W. performed the experiments. J.P.Z. generated the microbiota libraries and performed the corresponding bioinformatics analysis. L.D., T.K., V.K.V., G.V., L.J.C., and P.D.S. helped with data analysis and interpretation. D.M., J.P.Z., and D.M.A. wrote the manuscript, and J.L.R., V.K.V., and E.P.S. proofread the manuscript.

D.M. was supported by a Career Development Award from the Crohn's and Colitis Foundation of America. J.P.Z. was supported by NIH-NIDDK grant no. T32DK007673 and NIH-NIAID grant no. F32AI120553. D.M.A. was supported by NIH-NCATS grants no. U01TR002398 and R21TR001723, and NIH-NIAID grant no. R21AI121796.

REFERENCES

1. Lessa FC, Gould CV, McDonald LC. 2012. Current status of *Clostridium difficile* infection epidemiology. *Clin Infect Dis* 55:S65–S70. <https://doi.org/10.1093/cid/cis319>.
2. Leffler DA, Lamont JT. 2015. *Clostridium difficile* infection. *N Engl J Med* 372:1539–1548. <https://doi.org/10.1056/NEJMra1403772>.
3. Buonomo EL, Petri WA. 2016. The microbiota and immune response during *Clostridium difficile* infection. *Anaerobe* 41:79–84. <https://doi.org/10.1016/j.anaerobe.2016.05.009>.
4. Lessa FC, Mu Y, Bamberg WM, Beldavs ZG, Dumyati GK, Dunn JR, Farley MM, Holzbauer SM, Meek JI, Phipps EC, Wilson LE, Winston LG, Cohen JA, Limbago BM, Fridkin SK, Gerding DN, McDonald LC. 2015. Burden of *Clostridium difficile* infection in the United States. *N Engl J Med* 372:825–834. <https://doi.org/10.1056/NEJMoa1408913>.
5. Collins J, Robinson C, Danhof H, Knetsch CW, Van Leeuwen HC, Lawley TD, Auchtung JM, Britton RA. 2018. Dietary trehalose enhances virulence of epidemic *Clostridium difficile*. *Nature* 553:291–294. <https://doi.org/10.1038/nature25178>.
6. Zackular JP, Moore JL, Jordan AT, Juttukonda LJ, Noto MJ, Nicholson MR, Crews JD, Semler MW, Zhang Y, Ware LB, Washington MK, Chazin WJ, Caprioli RM, Skaar EP. 2016. Dietary zinc alters the microbiota and decreases resistance to *Clostridium difficile* infection. *Nat Med* 22:1330–1334. <https://doi.org/10.1038/nm.4174>.
7. Abt MC, Lewis BB, Caballero S, Xiong H, Carter RA, Susac B, Ling L, Leiner I, Pamer EG. 2015. Innate immune defenses mediated by two ilc subsets are critical for protection against acute *Clostridium difficile* infection. *Cell Host Microbe* 18:27–37. <https://doi.org/10.1016/j.chom.2015.06.011>.
8. Garey KW, Jiang Z-D, Ghantaji S, Tam VH, Arora V, Dupont HL. 2010. A common polymorphism in the interleukin-8 gene promoter is associated with an increased risk for recurrent *Clostridium difficile* infection. *Clin Infect Dis* 51:1406–1410. <https://doi.org/10.1086/657398>.
9. Jarchum I, Liu M, Shi C, Equinda M, Pamer EG. 2012. Critical role for myd88-mediated neutrophil recruitment during *Clostridium difficile* colitis. *Infect Immun* 80:2989–2996. <https://doi.org/10.1128/IAI.00448-12>.
10. Madan R, Petri WA. 2012. Immune responses to *Clostridium difficile* infection. *Trends Mol Med* 18:658–666. <https://doi.org/10.1016/j.molmed.2012.09.005>.
11. Permpalung N, Upala S, Sanguankeo A, Sornprom S. 2016. Association between NSAIDs and *Clostridium difficile*-associated diarrhea: a systematic review and meta-analysis. *Can J Gastroenterol Hepatol* 2016:1. 7431838. <https://doi.org/10.1155/2016/7431838>.
12. Muñoz-Miralles J, Trindade BC, Castro-Córdova P, Bergin IL, Kirk LA, Gil F, Aronoff DM, Paredes-Sabja D. 2018. Indomethacin increases severity of *Clostridium difficile* infection in mouse model. *Future Microbiol* 13:1271–1281. <https://doi.org/10.2217/fmb-2017-0311>.
13. Liang X, Bittinger K, Xuanwen L, Abernethy DR, Bushman FD, Fitzgerald GA. 2015. Bidirectional interactions between indomethacin and the murine intestinal microbiota. *Elife* 4:e08973. <https://doi.org/10.7554/eLife.08973>.
14. Xiao X, Nakatsu G, Jin Y, Wong S, Yu J, Lau JYW. 2017. Gut microbiota mediates protection against enteropathy induced by indomethacin. *Sci Rep* 7:40317. <https://doi.org/10.1038/srep40317>.
15. Cryer B, Barnett MA, Wagner J, Wilcox CM. 2016. Overuse and misperceptions of nonsteroidal anti-inflammatory drugs in the United States. *Am J Med Sci* 352:472–480. <https://doi.org/10.1016/j.amjms.2016.08.028>.
16. Fowler TO, Durham CO, Planton J, Edlund BJ. 2014. Use of nonsteroidal anti-inflammatory drugs in the older adult. *J Am Assoc Nurse Pract* 26:414–423. <https://doi.org/10.1002/2327-6924.12139>.
17. Tonolini M. 2013. Acute nonsteroidal anti-inflammatory drug-induced colitis. *J Emerg Trauma Shock* 6:301–303. <https://doi.org/10.4103/0974-2700.120389>.
18. Villanacci V, Casella G, Bassotti G. 2011. The spectrum of drug-related colitides: important entities, though frequently overlooked. *Dig Liver Dis* 43:523–528. <https://doi.org/10.1016/j.dld.2010.12.016>.
19. Montrose DC, Nakanishi M, Murphy RC, Zarini S, McAleer JP, Vella AT, Rosenberg DW. 2015. The role of PGE2 in intestinal inflammation and tumorigenesis. *Prostaglandins Other Lipid Mediat* 116–117:26–36. <https://doi.org/10.1016/j.prostaglandins.2014.10.002>.
20. Blackler RW, De Palma G, Manko A, Da Silva GJ, Flannigan KL, Bercik P, Surette MG, Buret AG, Wallace JL. 2015. Deciphering the pathogenesis of NSAID enteropathy using proton pump inhibitors and a hydrogen sulfide-releasing NSAID. *Am J Physiol Liver Physiol* 308:G994–G1003. <https://doi.org/10.1152/ajpgi.00066.2015>.
21. Rogers MAM, Aronoff DM. 2016. The influence of nonsteroidal anti-inflammatory drugs on the gut microbiome. *Clin Microbiol Infect* 22:178.e1–178.e9. <https://doi.org/10.1016/j.cmi.2015.10.003>.
22. Syer SD, Blackler RW, Martin R, de Palma G, Rossi L, Verdu E, Bercik P, Surette MG, Aucouturier A, Langella P, Wallace JL. 2015. NSAID enteropathy and bacteria: a complicated relationship. *J Gastroenterol* 50:387–393. <https://doi.org/10.1007/s00535-014-1032-1>.
23. Xiao X, et al. 2017. Gut microbiota mediates protection against enteropathy induced by indomethacin. *Sci Rep* 7:40317. <https://doi.org/10.1038/srep40317>.
24. Buonomo EL, Madan R, Pramoongjago P, Li L, Okusa MD, Petri WA. 2013. Role of interleukin 23 signaling in *Clostridium difficile* colitis. *Int J Infect Dis* 208:917–920. <https://doi.org/10.1093/infdis/jit277>.
25. Hasegawa M, Kamada N, Jiao Y, Liu MZ, Núñez G, Inohara N. 2012. Protective role of commensals against *Clostridium difficile* infection via an IL-1 β -mediated positive-feedback loop. *J Immunol* 189:3085–3091. <https://doi.org/10.4049/jimmunol.1200821>.
26. Jafari NV, Kuehne SA, Bryant CE, Elawad M, Wren BW, Minton NP, Allan E, Bajaj-Elliott M. 2013. *Clostridium difficile* modulates host innate immunity via toxin-independent and dependent mechanism(s). *PLoS One* 8:e69846. <https://doi.org/10.1371/journal.pone.0069846>.
27. Kamada N, Chen GY, Inohara N, Núñez G. 2013. Control of pathogens and pathobionts by the gut microbiota. *Nat Immunol* 14:685–690. <https://doi.org/10.1038/ni.2608>.
28. Bjarnason I, Zanelli G, Smith T, Prouse P, Williams P, Smethurst P, Delacey G, Gumpel MJ, Levi AJ. 1987. Nonsteroidal anti-inflammatory drug-induced intestinal inflammation in humans. *Gastroenterology* 93:480–489.
29. Berg DJ, Zhang J, Weinstock JV, Ismail HF, Earle KA, Alila H, Pamukcu R, Moore S, Lynch RG. 2002. Rapid development of colitis in NSAID-treated IL-10-deficient mice. *Gastroenterology* 123:1527–1542.
30. Feuerstadt P. 25 June 2015. *Clostridium difficile* infection. *Clin Transl Gastroenterol* <https://doi.org/10.1038/ctg.2015.13>.
31. Mukherjee S, Hooper LV. 2015. Antimicrobial defense of the intestine. *Immunity* 42:28–39. <https://doi.org/10.1016/j.immuni.2014.12.028>.
32. Rao K, Erb-Downward JR, Walk ST, Micic D, Falkowski N, Santhosh K, Mogle JA, Ring C, Young VB, Huffnagle GB, Aronoff DM. 2014. The systemic inflammatory response to *Clostridium difficile* infection. *PLoS One* 9:e92578. <https://doi.org/10.1371/journal.pone.0092578>.
33. Shi C, Pamer EG. 2011. Monocyte recruitment during infection and inflammation. *Nat Rev Immunol* 11:762–774. <https://doi.org/10.1038/nri3070>.
34. Buffie CG, Jarchum I, Equinda M, Lipuma L, Gouberne A, Viale A, Ubeda C, Xavier J, Pamer EG. 2012. Profound alterations of intestinal microbiota following a single dose of clindamycin results in sustained susceptibility to *Clostridium difficile*-induced colitis. *Infect Immun* 80:62–73. <https://doi.org/10.1128/IAI.05496-11>.
35. Jenior ML, Leslie JL, Young VB, Schloss PD. 2017. *Clostridium difficile* colonizes alternative nutrient niches during infection across distinct murine gut microbiomes. *mSystems* 2:e00063-17. <https://doi.org/10.1128/mSystems.00063-17>.
36. Maier L, Pruteanu M, Kuhn M, Zeller G, Telzerow A, Anderson EE, Brochado AR, Fernandez KC, Dose H, Mori H, Patil KR, Bork P, Typas A. 2018. Extensive impact of non-antibiotic drugs on human gut bacteria. *Nature* 555:623–628. <https://doi.org/10.1038/nature25979>.
37. Evans CT, Safdar N. 2015. Current trends in the epidemiology and outcomes of *Clostridium difficile* infection. *Clin Infect Dis* 60:S66–S71. <https://doi.org/10.1093/cid/civ140>.
38. Abt MC, McKenney PT, Pamer EG. 2016. *Clostridium difficile* colitis: pathogenesis and host defence. *Nat Rev Microbiol* 14:609–620. <https://doi.org/10.1038/nrmicro.2016.108>.
39. Olsen MA, Yan Y, Reske KA, Zilberberg MD, Dubberke ER. 2015. Recurrent *Clostridium difficile* infection is associated with increased mortality. *Clin Microbiol Infect* 21:164–170. <https://doi.org/10.1016/j.cmi.2014.08.017>.
40. Newman KM, Rank KM, Vaughn BP, Khoruts A. 2017. Treatment of recurrent *Clostridium difficile* infection using fecal microbiota transplan-

- in patients with inflammatory bowel disease. *Gut Microbes* 8:303–309. <https://doi.org/10.1080/19490976.2017.1279377>.
41. Smits LP, Bouter KEC, De Vos WM, Borody TJ, Nieuwdorp M. 2013. Therapeutic potential of fecal microbiota transplantation. *Gastroenterology* 145:946–953. <https://doi.org/10.1053/j.gastro.2013.08.058>.
 42. Bojanova DP, Bordenstein SR. 2016. Fecal transplants: what is being transferred? *PLoS Biol* 14:e1002503. <https://doi.org/10.1371/journal.pbio.1002503>.
 43. Zhou Y, Boudreau DM, Freedman AN. 2014. Trends in the use of aspirin and nonsteroidal anti-inflammatory drugs in the general U.S. population. *Pharmacoepidemiol Drug Saf* 23:43–50. <https://doi.org/10.1002/pds.3463>.
 44. Ananthakrishnan AN, Higuchi LM, Huang ES, Khalili H, Richter JM, Fuchs CS, Chan AT. 2012. Aspirin, nonsteroidal anti-inflammatory drug use, and risk for Crohn disease and ulcerative colitis: a cohort study. *Ann Intern Med* 156:350–359. <https://doi.org/10.7326/0003-4819-156-5-201203060-00007>.
 45. Kelsen JR, Kim J, Latta D, Smathers S, McGowan KL, Zaoutis T, Mamula P, Baldassano RN. 2011. Recurrence rate of *Clostridium difficile* infection in hospitalized pediatric patients with inflammatory bowel disease. *Inflamm Bowel Dis* 17:50–55. <https://doi.org/10.1002/ibd.21421>.
 46. Kvasnovsky CL, Aujla U, Bjarnason I. 2015. Nonsteroidal anti-inflammatory drugs and exacerbations of inflammatory bowel disease. *Scand J Gastroenterol* 50:255–263. <https://doi.org/10.3109/00365521.2014.966753>.
 47. Sokol H, Lalande V, Landman C, Bourrier A, Nion-Larmurier I, Rajca S, Kirchgerner J, Seksik P, Cosnes J, Barbut F, Beaugerie L. 2017. *Clostridium difficile* infection in acute flares of inflammatory bowel disease: a prospective study. *Dig Liver Dis* 49:643–646. <https://doi.org/10.1016/j.dld.2017.01.162>.
 48. Kim H, Rhee SH, Pothoulakis C, LaMont JT. 2007. Inflammation and apoptosis in *Clostridium difficile* enteritis is mediated by PGE2 up-regulation of Fas ligand. *Gastroenterology* 133:875–886. <https://doi.org/10.1053/j.gastro.2007.06.063>.
 49. Miyoshi H, VanDussen KL, Malvin NP, Ryu SH, Wang Y, Sonnek NM, Lai C, Stappenbeck TS. 2017. Prostaglandin E2 promotes intestinal repair through an adaptive cellular response of the epithelium. *EMBO J* 36: 5–24. <https://doi.org/10.15252/embj.201694660>.
 50. Roulis M, Nikolaou C, Kotsaki E, Kaffe E, Karagianni N, Koliarakis V, Salpea K, Ragoussis J, Aidinis V, Martini E, Becker C, Herschman HR, Vetrano S, Danese S, Kollias G. 2014. Intestinal myofibroblast-specific Tpl2-Cox-2-PGE2 pathway links innate sensing to epithelial homeostasis. *Proc Natl Acad Sci* 111:E4658–E4667. <https://doi.org/10.1073/pnas.1415762111>.
 51. Stenson WF. 2007. Prostaglandins and epithelial response to injury. *Curr Opin Gastroenterol* 23:107–110. <https://doi.org/10.1097/MOG.0b013e3280143cb6>.
 52. Wells JM, Rossi O, Meijerink M, van Baarlen P. 2011. Epithelial crosstalk at the microbiota-mucosal interface. *Proc Natl Acad Sci* 108:4607–4614. <https://doi.org/10.1073/pnas.1000092107>.
 53. Lanas A, Sopena F. 2009. Nonsteroidal anti-inflammatory drugs and lower gastrointestinal complications. *Gastroenterol Clin North Am* 38: 333–352. <https://doi.org/10.1016/j.gtc.2009.03.007>.
 54. Nakanishi M, Rosenberg DW. 2013. Multifaceted roles of PGE2 in inflammation and cancer. *Semin Immunopathol* 35:123–137. <https://doi.org/10.1007/s00281-012-0342-8>.
 55. Schumacher Y, Aparicio T, Ourabah S, Baraille F, Martin A, Wind P, Dentin R, Postic C, Guilmeau S. 2016. Dysregulated CRTCL1 activity is a novel component of PGE2 signaling that contributes to colon cancer growth. *Oncogene* 35:2602–2614. <https://doi.org/10.1038/ncr.2015.283>.
 56. van Opstal E, Kolling GL, Moore JH, Coquery CM, Wade NS, Loo WM, Bolick DT, Shin JH, Erickson LD, Warren CA. 2016. Vancomycin treatment alters humoral immunity and intestinal microbiota in an aged mouse model of *Clostridium difficile* infection. *J Infect Dis* 214:130–139. <https://doi.org/10.1093/infdis/jiw071>.
 57. Agard M, Asakrah S, Morici LA. 2013. PGE(2) suppression of innate immunity during mucosal bacterial infection. *Front Cell Infect Microbiol* 3:45. <https://doi.org/10.3389/fcimb.2013.00045>.
 58. Duffin R, O'Connor RA, Crittenden S, Forster T, Yu C, Zheng X, Smyth D, Robb CT, Rossi F, Skouras C, Tang S, Richards J, Pellicoro A, Weller RB, Breyer RM, Mole DJ, Iredale JP, Anderton SM, Narumiya S, Maizels RM, Ghazal P, Howie SE, Rossi AG, Yao C. 2016. Prostaglandin E2 constrains systemic inflammation through an innate lymphoid cell-IL-22 axis. *Science* 351:1333–1338. <https://doi.org/10.1126/science.aad9903>.
 59. Yao C, Sakata D, Esaki Y, Li Y, Matsuoka T, Kuroiwa K, Sugimoto Y, Narumiya S. 2009. Prostaglandin E2–EP4 signaling promotes immune inflammation through TH1 cell differentiation and TH17 cell expansion. *Nat Med* 15:633–640. <https://doi.org/10.1038/nm.1968>.
 60. Loynes CA, Lee JA, Robertson AL, Steel MJ, Ellett F, Feng Y, Levy BD, Whyte MKB, Renshaw SA. 2018. PGE2 production at sites of tissue injury promotes an anti-inflammatory neutrophil phenotype and determines the outcome of inflammation resolution in vivo. *Sci Adv* 4:eaar8320. <https://doi.org/10.1126/sciadv.aar8320>.
 61. Newson J, Motwani MP, Kendall AC, Nicolaou A, Muccioli GG, Alhouayek M, Bennett M, Van De Merwe R, James S, De Maeyer RPH, Gilroy DW. 2017. Inflammatory resolution triggers a prolonged phase of immune suppression through COX-1/mPGEs-1-derived prostaglandin E2. *Cell Rep* 20:3162–3175. <https://doi.org/10.1016/j.celrep.2017.08.098>.
 62. Johnston PF, Gerding DN, Knight KL. 2014. Protection from *Clostridium difficile* infection in CD4 T cell- and polymeric immunoglobulin receptor-deficient mice. *Infect Immun* 82:522–531. <https://doi.org/10.1128/IAI.01273-13>.
 63. Duque GA, Descoteaux A. 2014. Macrophage cytokines: involvement in immunity and infectious diseases. *Front Immunol* 5:491. <https://doi.org/10.3389/fimmu.2014.00491>.
 64. Mcsorley SJ. 2014. Immunity to intestinal pathogens: lessons learned from Salmonella. *Immunol Rev* 260:168–182. <https://doi.org/10.1111/imr.12184>.
 65. Sonnenberg GF, Artis D. 2015. Innate lymphoid cells in the initiation, regulation and resolution of inflammation. *Nat Med* 21:698–708. <https://doi.org/10.1038/nm.3892>.
 66. Ishida Y, Maegawa T, Kondo T, Kimura A, Iwakura Y, Nakamura S, Mukaida N. 2004. Essential involvement of IFN-gamma in *Clostridium difficile* toxin A-induced enteritis. *J Immunol* 172:3018–3025.
 67. Yu H, Chen K, Sun Y, Carter M, Garey KW, Savidge TC, Devaraj S, Tessier ME, Von Rosening EC, Kelly CP, Pasetti MF, Feng H. 4 August 2017. Cytokines are markers of the *Clostridium difficile*-induced inflammatory response and predict disease severity. *Clin Vaccine Immunol* <https://doi.org/10.1128/CVI.00037-17>.
 68. Lee JS, Tato CM, Joyce-Shaikh B, Gulen MF, Gulan F, Cayatte C, Chen Y, Blumenschein WM, Judo M, Ayanoglu G, McClanahan TK, Li X, Cua DJ. 2015. Interleukin-23-independent IL-17 production regulates intestinal epithelial permeability. *Immunity* 43:727–738. <https://doi.org/10.1016/j.immuni.2015.09.003>.
 69. McDermott AJ, Falkowski NR, McDonald RA, Pandit CR, Young VB, Huffnagle GB. 2016. Interleukin-23 (IL-23), independent of IL-17 and IL-22, drives neutrophil recruitment and innate inflammation during *Clostridium difficile* colitis in mice. *Immunology* 147:114–124. <https://doi.org/10.1111/imm.12545>.
 70. Becattini S, Taur Y, Pamer EG. 2016. Antibiotic-induced changes in the intestinal microbiota and disease. *Trends Mol Med* 22:458–478. <https://doi.org/10.1016/j.molmed.2016.04.003>.
 71. Aden K, Rehman A, Falk-Paulsen M, Secher T, Kuiper J, Tran F, Pfeuffer S, Sheibani-Tezerji R, Breuer A, Luzius A, Jentzsch M, Häsler R, Billmann-Born S, Will O, Lipinski S, Bharti R, Adolph T, Iovanna JL, Kempster SL, Blumberg RS, Schreiber S, Becher B, Chamailard M, Kaser A, Rosenstiel P. 2016. Epithelial IL-23R signaling licenses protective IL-22 responses in intestinal inflammation. *Cell Rep* 16:2208–2218. <https://doi.org/10.1016/j.celrep.2016.07.054>.
 72. Cowardin CA, Kuehne SA, Buonomo EL, Marie CS, Minton NP, Petri WA. 2015. Inflammasome activation contributes to interleukin-23 production in response to *Clostridium difficile*. *mBio* 6:e02386-14. <https://doi.org/10.1128/mBio.02386-14>.
 73. Lee YS, Yang H, Yang JY, Kim Y, Lee SH, Kim JH, Jang YJ, Vallance BA, Kweon MN. 2015. Interleukin-1 (IL-1) signaling in intestinal stromal cells controls KC/CXCL1 secretion, which correlates with recruitment of IL-22-secreting neutrophils at early stages of *Citrobacter rodentium* infection. *Infect Immun* 83:3257–3267. <https://doi.org/10.1128/IAI.00670-15>.
 74. Roxas JL, Viswanathan VK. 2018. Modulation of intestinal paracellular transport by bacterial pathogens. *Compr Physiol* 8:823–842. <https://doi.org/10.1002/cphy.c170034>.
 75. Marchiando AM, Shen L, Vallen Graham W, Weber CR, Schwarz BT, Austin JR, Raleigh DR, Guan Y, Watson AJM, Montrose MH, Turner JR. 2010. Caveolin-1-dependent occludin endocytosis is required for TNF-induced tight junction regulation in vivo. *J Cell Biol* 189:111–126. <https://doi.org/10.1083/jcb.200902153>.
 76. Chen X, Katchar K, Goldsmith JD, Nanthakumar N, Cheknis A, Gerding DN, Kelly CP. 2008. A mouse model of *Clostridium difficile*-associated

- disease. *Gastroenterology* 135:1984–1992. <https://doi.org/10.1053/j.gastro.2008.09.002>.
77. Theriot CM, Koumpouras CC, Carlson PE, Bergin II, Aronoff DM, Young VB. 2011. Cefoperazone-treated mice as an experimental platform to assess differential virulence of *Clostridium difficile* strains. *Gut Microbes* 2:326–334. <https://doi.org/10.4161/gmic.19142>.
 78. Imhann F, Vich Vila A, Bonder MJ, Fu J, Gevers D, Visschedijk MC, Spekhorst LM, Alberts R, Franke L, van Dullemen HM, Ter Steege RWF, Huttenhower C, Dijkstra G, Xavier RJ, Festen EAM, Wijmenga C, Zhernakova A, Weersma RK. 2018. Interplay of host genetics and gut microbiota underlying the onset and clinical presentation of inflammatory bowel disease. *Gut* 67:108–119. <https://doi.org/10.1136/gutjnl-2016-312135>.
 79. Pascal V, Pozuelo M, Borruel N, Casellas F, Campos D, Santiago A, Martinez X, Varela E, Sarabayrouse G, Machiels K, Vermeire S, Sokol H, Guarner F, Manichanh C. 2017. A microbial signature for Crohn's disease. *Gut* 66:813–822. <https://doi.org/10.1136/gutjnl-2016-313235>.
 80. Seregin SS, Golovchenko N, Schaf B, Chen J, Pudlo NA, Mitchell J, Baxter NT, Zhao L, Schloss PD, Martens EC, Eaton KA, Chen GY. 2017. NLRP6 protects Il10^{-/-} mice from colitis by limiting colonization of *Akkermansia muciniphila*. *Cell Rep* 19:733–745. <https://doi.org/10.1016/j.celrep.2017.03.080>.
 81. Tedjo DI, Smolinska A, Savelkoul PH, Masclee AA, Van Schooten FJ, Pierik MJ, Penders J, Jonkers DMAE. 13 October 2016. The fecal microbiota as a biomarker for disease activity in Crohn's disease. *Sci Rep* <https://doi.org/10.1038/srep35216>.
 82. Schubert AM, Rogers MAM, Ring C, Mogle J, Petrosino JP, Young VB, Aronoff DM, Schloss PD. 2014. Microbiome data distinguish patients with *Clostridium difficile* infection and non-*C. difficile*-associated diarrhea from healthy controls. *mBio* 5:e01021-14. <https://doi.org/10.1128/mBio.01021-14>.
 83. Hepworth MR, Monticelli LA, Fung TC, Ziegler CGK, Grunberg S, Sinha R, Mantegazza AR, Ma H-L, Crawford A, Angelosanto JM, Wherry EJ, Koni PA, Bushman FD, Elson CO, Eberl G, Artis D, Sonnenberg GF. 2013. Innate lymphoid cells regulate CD4⁺ T-cell responses to intestinal commensal bacteria. *Nature* 498:113–117. <https://doi.org/10.1038/nature12240>.
 84. Knoop KA, McDonald KG, Kulkarni DH, Newberry RD. 2016. Antibiotics promote inflammation through the translocation of native commensal colonic bacteria. *Gut* 65:1100–1109. <https://doi.org/10.1136/gutjnl-2014-309059>.
 85. Batah J, Kobeissy H, Pham PTB, Denève-Larrazet C, Kuehne S, Collignon A, Janoir-Jouveshomme C, Marvaud JC, Kansau I. 2017. *Clostridium difficile* flagella induce a pro-inflammatory response in intestinal epithelium of mice in cooperation with toxins. *Sci Rep* 7:3256. <https://doi.org/10.1038/s41598-017-03621-z>.
 86. Kozich JJ, Westcott SL, Baxter NT, Highlander SK, Schloss PD. 2013. Development of a dual-index sequencing strategy and curation pipeline for analyzing amplicon sequence data on the MiSeq Illumina sequencing platform. *Appl Environ Microbiol* 79:5112–5120. <https://doi.org/10.1128/AEM.01043-13>.
 87. Schloss PD, Westcott SL, Ryabin T, Hall JR, Hartmann M, Hollister EB, Lesniewski RA, Oakley BB, Parks DH, Robinson CJ, Sahl JW, Stres B, Thallinger GG, Van Horn DJ, Weber CF. 2009. Introducing mothur: open-source, platform-independent, community-supported software for describing and comparing microbial communities. *Appl Environ Microbiol* 75:7537–7541. <https://doi.org/10.1128/AEM.01541-09>.
 88. Nakagawa T, Mori N, Kajiwara C, Kimura S, Akasaka Y, Ishii Y, Saji T, Tateda K. 2016. Endogenous IL-17 as a factor determining the severity of *Clostridium difficile* infection in mice. *J Med Microbiol* 65:821–827. <https://doi.org/10.1099/jmm.0.000273>.
 89. O'Connor JR, et al. 2009. *Clostridium difficile* infection caused by the epidemic BI/NAP1/027 strain. *Gastroenterology* 136:1913–1924. <https://doi.org/10.1053/j.gastro.2009.02.073>.
 90. Segata N, et al. 2011. Metagenomic biomarker discovery and explanation. *Genome Biology* 12:R60. <https://doi.org/10.1186/gb-2011-12-6-r60>.